Inclusion Criteria: * Age greater than or equal to 55 years; * Subfoveal CNV secondary to AMD and with best corrected visual acuity of 3/60 - 6/9 with 6/60 or better in the other eye; * Fluorescein angiogram of the study eye must show evidence of a leaking subfoveal choroidal neovascular lesion, or CNV currently under active management with anti-VEGF therapy; * Must be a candidate for anti-VEGF intravitreal injections; * No previous retinal treatment of photodynamic therapy or laser; * Able to provide informed consent; * Able to comply with protocol requirements, including follow-up visits. Exclusion Criteria: * Liver enzymes \> 2 X upper limit of normal; * Any prior treatment for AMD in the study / control eye, excluding anti-VEGF injections; * Extensive sub-foveal scarring, extensive geographic atrophy, or thick subretinal blood in the study eye as determined by the investigator; * Significant retinal disease other than sub-foveal CNV AMD;